Stock AnalizAlvotech ALVO
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Alvotech (ALVO) is a healthcare company listed in the US with a market value of about $1.5B. In the twelve months to June 30, 2026 it had revenue of $492M and net income of -$180M, a net margin of -36.5%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 54% a year, a 5-year average ROIC of -259%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 29% below the current price.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 5-year revenue growth above 8% a year
- Interest covered more than 5 times
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $492M | $586M | $490M | $91M | $83M | $37M | $67M |
| Net income | -$180M | $28M | -$232M | -$552M | -$514M | -$102M | -$170M |
| Free cash flow | -$334M | -$115M | -$291M | -$345M | -$350M | -$249M | -$82M |
| EPS (diluted) | $-0.61 | $0.08 | $-0.65 | $-1.55 | $-1.44 | $-0.28 | $-0.48 |
| Net margin | -36.5% | 4.8% | -47.3% | -603.4% | -618.6% | -276.0% | -255.3% |
| ROIC | — | 6.1% | 8.4% | -1087.0% | -161.1% | -60.4% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $7.50, 79% above the current price; targets range from $4.00 to $9.00; the consensus rating is “Buy”; expected EPS is $-0.04 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Alvotech stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 29% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Alvotech pay a dividend?
Not currently.
Is Alvotech a good stock to buy?
We do not give buy or sell advice. Alvotech scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.